Yuexin Yu

Yuexin Yu is a Director on the Life Sciences team at Andera Partners, where he leads investment strategy and portfolio company oversight within the global biopharmaceutical sector. Before joining Andera, he executed healthcare investments at 3H Health Investment Management and managed the commercial product lifecycles for blockbuster drugs Remicade and Keytruda at MSD. His earlier career includes strategic roles at bioMérieux's corporate venture arm and Biotheranostics, supported by a pharmacy degree from Shanghai Jiao Tong University and a business degree from HEC Paris. Yu has backed numerous successful life sciences companies, contributing to significant portfolio exits such as Amolyt's acquisition by AstraZeneca, ReViral's sale to Pfizer, and LogicBio's acquisition by Alexion. His active investment portfolio includes clinical-stage developers like Mineralys Therapeutics, Tubulis, and Evommune. He currently focuses on funding novel biopharmaceutical therapies targeting hypertension, oncology, and thrombotic diseases.